Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

NCT05265793 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05265793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05265793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
November 21, 2021
Completion date
June 30, 2023
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinosarcoma, pd-1 immunotherapy, sarcomatoid carcinoma, vegfr-tki